650 694 5740 Stemens Medical 03:42:14 p.m. 10-13-2008

RECEIVED

1 /47

## ATTORNEY DOCKET NO .: 2004P01660BENTRAL FAX CENTE IN THE UNITED STATES PATENT AND TRADEMARK OFFICE OCT 1 4 2008

Inventor(s): Ustuner et al. CERTIFICATE OF EXPRESS MAIL, MAILING OR FACSIMILE TRANSMISSION Appin, No.: 10/814.959

The undersigned hereby certifles that this correspondence is being deposited under Express Mail Label No. \_\_\_\_ on the date Filing Date: 03/31/2004

given below; or being deposited under 37 CFR 1.8 with the U.S. Postal Service COHERENCE FACTOR ADAPTIVE ULTRASOUND IMAGING METHODS AND Title: with sufficient postage as first class mail in an envelope addressed to

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date given below, or SYSTEMS being facslmile transmitted to the U.S. Patent and Trademark

Office at the fax number and date given below:
Facsimile Number 571-273-8300
No. of Pages: total pages Examiner: Joel Lamprecht

571-273-8300 tota Date of Depos Typed Nan

3737

Art Unit:

Aail Stop Amendment COMMISSIONER FOR PATENTS 105 H30 Beandria, VA 22313-1450			
	INFORMATION DISCLOSURE STATEMENT		
ir:	This Information Disclosure Statement is submitted:		
		under 37 CFR 1.97 (b).  Within three months of either ☐ the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d) or ☐ the date of national stage entry of international application; or ☐ before mailing date of first office action on the metrix ☐ before mailing date of a first office action after filing of a request for continued examination under 37 CFR 1.14).	
	⊠	under 37 CFR 1.97 (c) together with either a:    Certification under 37 CFR 1.97 (c) 1.77 (p) authorized to be charged to Deposit Account 19- 2179. At any time during the pendency of this application, please charge any less required or credit any overpayment to Deposit Account 19-2179 our suant to 37 CFR 1.25 (c) (After the 37 CFR 1.37 (c) time period, but before mailing date of any of a final action under 37 CFR 1.113, or a notice of allowance under 37 CFR 1.311, or an action that otherwise closes prosecution.	
		under 37 CFR 1.97 (d) together with a: Certification under 37 CFR 1.97 (e). AND the \$\frac{1}{2}\$ (1.90 \) (2.90 \) (2.90 \) the \$\frac{1}{2}\$ (1.90 \) (2.90 \) (3.90 \) the \$\frac{1}{2}\$ (1.90 \) (3.90 \) (4.90 \) (4.90 \) (5.90 \) (5.90 \) (5.90 \) (5.90 \) (5.90 \) (5.90 \) (5.90 \) (5.90 \) (5.90 \) (5.90 \) (6.90 \) (6.90 \) (6.90 \) (7.9	
		under 37 CFR 1.97 (i) (Filed after time period of 37 CFR 1.97 (d) or not in compliance with 37 CFR 1.97 or 1.98 - No fee or certification required; references to be placed in file but not considered).	
plicant(s) submit herewith Form PTO 1449 - Information Disclosure Citation which applicant(s) believe(s) may			

Applicani(s) submit herewith Form PTO 1449 - Information Disclosure Citation which applicani(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accidence with the properties of th

10/14/2008 VBUI11 80000030 192179 10814959

01 FC:1886

188.88 DA

PAGE 1/47 \* RCVD AT 10/13/2008 7:39:25 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/19 \* DNIS:2738300 \* CSID:650 694 5740 \* DURATION (mm-ss):15-24

650 694 5740 03:42:31 p.m. Slemens Medical 10-13-2008 2 //7

The undersigned hereby certifies under 37 CFR 1.97(e)(1) that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. On the undersigned certifies under 37 CFB 1.07(1)(2)

statement: OH
The undersigned certifies under 37 CFR 1.97(e)(2) that no item of information contained in the
information disclosure statement was cited in a communication from a foreign patient office in a counterpart
foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of
information contained in the information disclosure statement was known to any individual designated in 37 CFR
1.55(c) more than three months prior to the filling of the information disclosure statement.

A concise explanation of the relevance of foreign language patents, foreign language publications and other foreign language information listed on PTO Form 1449, as presently understood by the individuals) arise designated in 37 CFR 1.56 (or most knowledgeable about the content that is green the information of the property of the pr

Applicant does not believe any fee is due. However, at any time during the pendency of this application, please charge any fees required or credit any overpayment to Deposit Account 19-2179 pursuant to 37 CFR 1.25. A duplicate copy of this sheet is enclosed.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made or that no other material information exists. Further, the filing of this information disclosure statement shall not be construed as an admission against interest in any manner or as an admission that the information cited is or is considered to be material to patentability.

PLEASE MAIL CORRESPONDENCE TO:

Siemens Corporation Customer No. 28524 Attn: Fisa Keller, Legal Administrator 170 Wood Avenue South Iselin, NJ 08830

Respectfully submitted.

Rosa S. Kim. Reg. No. 39,728 Attorney(s) for Applicant(s) Telephone: 650-694-5330 Date: 10-13-08